Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Article
en En
| MEDLINE
| ID: mdl-32178765
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Artritis Psoriásica
/
Factor de Necrosis Tumoral alfa
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Lancet
Año:
2020
Tipo del documento:
Article